| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation |
|
Medicine details |
|
| Medicine name | durvalumab (Imfinzi®) |
| Formulation | 50 mg/ml concentrate for solution for infusion |
| Reference number | 3660 |
| Indication | Monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/12/2019 |
| NICE guidance | |
| Commercial arrangement | PAS + CAA |